Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Serina Therapeutics, Inc. (SER : AMEX)

• Company Description    Serina Therapeutics Inc. is a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases. Serina Therapeutics Inc., formerly known as AgeX Therapeutics Inc., is based in HUNTSVILLE, Ala. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $5.90 Daily Weekly Monthly 20 Day Moving Average: 9,815 shares Shares Outstanding: 9.97 (millions) Market Capitalization: $58.77 (millions) Beta: 0.71 52 Week High: $11.57 52 Week Low: $3.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.49% -4.22% 12 Week 12.31% -5.54% Year To Date 17.68% 10.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 601 GENOME WAY SUITE 2001 - HUNTSVILLE,AL 35806 USA ph: 256-327-9630 fax: 510-671-8619 None https://serinatherapeutics.com

• General Corporate Information    Officers Steve Ledger - Chief Executive Officer and Director Balkrishan Gill - Executive Chairman of the Board of Directors Gregory S. Curhan - Chief Financial Officer Remy Gross - Director Richard Marshall - Director Peer Information Serina Therapeutics, Inc. (CORR.) Serina Therapeutics, Inc. (RSPI) Serina Therapeutics, Inc. (CGXP) Serina Therapeutics, Inc. (BGEN) Serina Therapeutics, Inc. (GTBP) Serina Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81751A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 9.97 Most Recent Split Date: 3.00 (0.03:1) Beta: 0.71 Market Capitalization: $58.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 37.70 Price/Cash Flow: - Price / Sales: 18.62 EPS Growth vs. Year Ago Period: 85.50% vs. Previous Quarter: -81.48% Sales Growth vs. Year Ago Period: -79.10% vs. Previous Quarter: -72.55% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -11.89 12/31/24 - -62.29 Current Ratio 06/30/25 - - 03/31/25 - 2.45 12/31/24 - 2.40 Quick Ratio 06/30/25 - - 03/31/25 - 2.45 12/31/24 - 2.40 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,988.23 12/31/24 - -20,012.50 Book Value 06/30/25 - - 03/31/25 - 0.16 12/31/24 - 0.06 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©